Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03603808 · ClinicalTrials.gov registry record · Phase 2
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
A Phase 2 study, sponsored by AIDS Malignancy Consortium.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT03603808 is a Phase 2 study that has completed, run by AIDS Malignancy Consortium. The registered enrollment target is 44 participants.
The verdict
NCT03603808, a Phase 2 study, has completed, sponsored by AIDS Malignancy Consortium.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporation together may work better in treating patients with high-grade anal lesions.
Interventions
- OTHER Laboratory Biomarker Analysis
- DEVICE Electroporation
- BIOLOGICAL HPV DNA Plasmids Therapeutic Vaccine VGX-3100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-09-21 |
| Est. Completion | 2025-06-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03603808
The ClinicalTrials.gov registry entry for NCT03603808 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AIDS Malignancy Consortium, which has 45 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03603808 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03603808 about?
NCT03603808 is a clinical study titled "VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions". This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body b...
What is the current status of trial NCT03603808?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2018-09-21. Estimated completion is 2025-06-17.
What interventions are being tested in trial NCT03603808?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Electroporation (DEVICE), HPV DNA Plasmids Therapeutic Vaccine VGX-3100 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03603808?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.